Warner Chilcott sees major jump in revenue

Warner Chilcott saw a big increase in 2009 revenue thanks to its acquisition of Proctor and Gamble’s branded pharmaceuticals business.

Warner’s total sales for the full year were $1.44 billion, up 45% on 2008, and its biggest growth driver was the oral contraceptive Loestrin, which grew 20% to $247 million.

Its dermatology portfolio, including Doryx, Taclonex and Dovonex, collectively made $480 million growing by in 9% 2009.

Warner’s sales performance enabled it to turn in profits of $514 million, reversing the $8million loss it recorded in 2008.

Plans to re-locate headquarters

Meanwhile the company is planning to move its headquarters in Ireland from Ardee to Dundalk.

It will re-locate executive offices, manufacturing operations and service support and aims to recruit to fill 200 positions at the new location over the next five years.

Minister for enterprise, trade and employment Mary Coughlan said: “I am delighted that Warner Chilcott has chosen Dundalk for this important operation. This development is excellent news for the North-East region and Ireland as a whole.

She continued: “Dundalk is one of Ireland’s busiest economic corridors, between Dublin and Belfast, and today’s announcement will bring new high quality employment opportunities to the region.”

Fifteen of the top twenty global pharma companies have established sites in the country, aided by its tax-break status, economic strengths and integration with the traditionally strong Euro Zone.